TAZOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C9H16N2O2S
Molecular Weight	216.301
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NCC(O)COC1=NC=CS1

InChI

InChIKey=DREVJBVJBRSSDL-UHFFFAOYSA-N

InChI=1S/C9H16N2O2S/c1-7(2)11-5-8(12)6-13-9-10-3-4-14-9/h3-4,7-8,11-12H,5-6H2,1-2H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10864 | https://www.ncbi.nlm.nih.gov/pubmed/235834

Tazolol is a selective myocardial beta-blocking agent. Experiments on dogs have shown that this compound could be useful in patients with heart failure due to coronary artery disease. However, information about the current use of tazolol is not available.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87 Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10864 \| https://www.ncbi.nlm.nih.gov/pubmed/2858837 \| https://www.ncbi.nlm.nih.gov/pubmed/2982014	Agonist 2678

PubMed

Title	Date	PubMed
Beta2-adrenergic stimulation of thyroid hormone secretion.	1975 Aug	239845

Patents

Name

Type

Language

TAZOLOL

Official Name

English

(±)-1-(ISOPROPYLAMINO)-3-(2-THIAZOLYLOXY)-2-PROPANOL

Systematic Name

English

tazolol [INN]

Common Name

English

2-PROPANOL, 1-((1-METHYLETHYL)AMINO)-3-(2-THIAZOLYLOXY)-, (±)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576